ffective micellar nanocarriers can improve the pharmacokinetics, biodistribution, toxicity profile, and efficacy of drug molecules and have been investigated extensively. 1À10 In order to maximize their therapeutic efficacy, micelle-based delivery systems should demonstrate (1) extended in vivo circulation half-life; (2) minimum cargo leakage during circulation; (3) controlled size for effective extravasations; and (4) degradation for eventual renal clearance to reduce systemic toxicity. When administered intravenously, nanoscopic carriers offer the added advantage of concentrating in tumor tissues via the enhanced permeation and retention (EPR) effect defined by leaky vasculature and poor lymphatic drainage commonly seen in solid tumors. 11À14 The size of the nanocarrier is considered the most critical factor to fully take advantage of the EPR effect. The physiological factors, including the density and heterogeneity of the vasculature at the tumor site and interstitial fluid pressure, impact the extent of extravasation of nanocarriers into tumors. Current FDA-approved Doxil (∼100 nm) and Abraxane (∼130 nm) have provided only modest survival benefits presumably due to inefficient transport of the chemotherapeutic drug into the tumor.
ffective micellar nanocarriers can improve the pharmacokinetics, biodistribution, toxicity profile, and efficacy of drug molecules and have been investigated extensively. 1À10 In order to maximize their therapeutic efficacy, micelle-based delivery systems should demonstrate (1) extended in vivo circulation half-life; (2) minimum cargo leakage during circulation; (3) controlled size for effective extravasations; and (4) degradation for eventual renal clearance to reduce systemic toxicity. When administered intravenously, nanoscopic carriers offer the added advantage of concentrating in tumor tissues via the enhanced permeation and retention (EPR) effect defined by leaky vasculature and poor lymphatic drainage commonly seen in solid tumors. 11À14 The size of the nanocarrier is considered the most critical factor to fully take advantage of the EPR effect. The physiological factors, including the density and heterogeneity of the vasculature at the tumor site and interstitial fluid pressure, impact the extent of extravasation of nanocarriers into tumors. Current FDA-approved Doxil (∼100 nm) and Abraxane (∼130 nm) have provided only modest survival benefits presumably due to inefficient transport of the chemotherapeutic drug into the tumor. 15 Studies have shown that following extravasation into tumor interstitium, a drug or drugencapsulated vehicle should be capable of travelling up to 100 μm away from the tumor vasculature in order to reach all cells within the tumor. 16 There is increasing evidence that a drug's limited penetration and distribution within a tumor, which results in insufficient elimination of malignant cells, may contribute to tumor repopulation after treatment. 17À20 Nanocarriers need to be below a certain size to achieve significant tumor penetration, 16, 21 and the size cutoff value depends on the shape, hardness, and architecture of the carrier. 22, 23 Recent studies using a 3D human melanoma xenograft model in mice showed that smaller particles (i.e., 10À12 nm quantum dots) can more effectively penetrate the physiological barriers imposed by abnormal tumor vasculature and dense interstitial matrix than the 60 nm nanoparticles. 21 Using dendrimers, the physiologic upper limit of pore size in the bloodÀ tumor barrier of malignant solid tumor microvasculature is determined to be approximately 12 nm. 24 Organic nanoparticles based on elastinlike peptides, ∼25 nm in size, demonstrated a nearly complete tumor regression in a murine cancer model. 25 There is a strong need to design and synthesize stable nanocarriers in the size range of 10À30 nm for potentially enhanced therapeutic efficacy. The effectiveness of a drug carrier depends on its stability and drug retention in vivo. After systemic injections, the nanocarriers are confronted with dilution, as well as numerous components, such as proteins and cells, which can lead to cargo leakage. To ensure an improvement in the toxicity profile of the drug, the drug needs to be retained within micelles until reaching the target site. The kinetic stability of micelles determines the in vivo stability, circulation half-life, and clearance pathway. 26, 27 As compared to covalent organic particles, micelles have very low intermolecular interactions among amphiphiles, typically a few kcal per mol. The subunit can exchange with local medium or among particles. The kinetic energy barrier of the exchange decreases as the micelle size reduces, especially when the size is below 20 nm. Small micelles are generally fluid, dynamic assemblies, where the subunit amphiphiles are constantly exchanging with the surrounding media and with other micelles. The presence of chemical traps in vivo that stabilize individual amphiphiles further reduces the stability of micelles and leads to undesirable cargo leakage and disassembly.
28À32
In addition to the control on particle size and cargo stability, an equally important requirement for effective nanocarriers is the balance of long circulation and nanocarrier clearance.
33À35 Nanocarriers initially must be larger than 6 nm to achieve extended circulation lifetime and subsequently need to disintegrate into materials smaller than ∼6 nm or 50 kDa in molecular weight to be eliminated from circulation by glomerular filtration in the kidney. 33 Chemically cross-linking the headgroups of an amphiphile and/or engineering multiple pairs of intermolecular interactions among the headgroups can be effective to obtain stable micelles. However, biodistribution studies indicated accumulation in the liver and spleen and raised concerns over the potential long-term toxicity. 36 Taking all of the design criteria into consideration, it is highly desirable to generate micellar nanocarriers in the size range of 10À30 nm which combine a long circulation half-life, effective tumor tissue penetration, minimal cargo leakage, and efficient subunit clearance. To meet these requirements, we have synthesized small micelles by designing a new family of amphiphiles based on coiled-coil 3-helix bundle forming peptideÀpoly(ethylene glycol) conjugates. The designed amphiphiles form stable micelles, so-called "3-helix micelles", 15 nm in size. The 3-helix micelles demonstrated significantly enhanced stability in comparison to existing micelles in similar size range. Förster resonance energy transfer (FRET) studies showed minimal cargo leakage over 12 h in the presence of serum proteins at 37°C. More importantly, in vivo pharmacokinetics studies using positron emission tomography (PET) showed a circulation half-life of 29.5 h. Additionally, the 3-helix micelle can be degraded and cleared with significantly reduced accumulation in the liver and spleen. These desirable attributes, including <20 nm particle size, long blood circulation, minimal cargo leakage, and efficient clearance, clearly validate the potential of 3-helix micelles as nanocarriers to meet current demands in nanomedicine.
RESULTS AND DISCUSSION
Amphiphilic PeptideÀPolymer Design and Synthesis. The amphiphile is schematically shown in Scheme 1. 
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The headgroup is composed of a newly designed peptideÀpoly(ethylene glycol) (PEG) conjugate where the PEG chain is attached to the middle of a 3-helix bundle forming peptide (protein data bank code 1coi). 37, 38 Structural studies and molecular dynamic simulation showed that the PEG chains locate in the exterior of the 3-helix bundle and stabilize the peptide's secondary and tertiary structures. 38, 39 Two C18 alkyl chains were attached at the peptide N-terminus with a (6)-amino-hexanoic acid linker inserted between the peptide and the alkyl tail to introduce amphiphilicity. Another PEG chain is attached to the peptide C-terminus to provide a stealth layer in a similar fashion to that of PEGylated liposomes. 40, 41 The resulting amphiphile is termed as "1coi-dC18-PEG2K". The intermolecular interactions between peptides and the compression of PEG on the exterior of the helix bundle increase the activation energy barrier for subunit desorption and provide stability to the micelle. Upon forming micelles, peptideÀ PEG conjugates in the headgroup will self-associate into a trimeric subunit (Scheme 1b) and may provide a platform to investigate the effect of the oligomeric state of ligand presentation on the active targeting for nanocarrier localization. The PEG chains attached to the exterior of the helix bundle may be used to tailor the interligand cluster distance. The peptide 1coi (EVEALEKKVAALECKVQALEKKVE-ALEHGW) was synthesized using solid-phase peptide synthesis (SPPS). The synthetic methodology for the amphiphiles is shown in Figure 1 . Specifically, the alkyl chains were conjugated on solid phase through reaction of stearic acids with deprotected Fmoc-Lys(Fmoc)-OH to generate a branched alkyl tail at the N-terminus. Orthogonal protectionÀdeprotection strategies were employed to link PEG molecules on both the side and the C-terminus. The C-terminus was modified through palladium-catalyzed allyl deprotection of FmocLys(Alloc)-OH followed by conjugation of carboxyterminated organic molecules using HBTU/DIPEA chemistry. In this study, PEG (M w = 750 Da) was selected as the C-terminal functional group to generate a stealth layer to prevent nonspecific protein absorption. A variety of targeting ligands can also be attached using the same chemistry. The conjugate was purified by reverse-phase high-pressure liquid chromatography (RP-HPLC) using a gradient of mixed solvents containing water (0.1% TFA) and isopropyl alcohol (0.1% TFA). The amphiphilic molecules eluted at ∼85% isopropyl alcohol with the overall yield of 30%. The molecular weight was confirmed by MALDI-TOF spectrometry ( Figure 1 ).
Physical Characterization of Amphiphilic Micelles. The amphiphile 1coi-dC18-PEG2K spontaneously selfassembles into micelles above its CMC value (∼2 μM) in aqueous solution. Figure 2a shows the circular dichroism (CD) spectrum of 200 μM solution of 1coi-dC18-PEG2K at 25°C in phosphate buffer (pH = 7.4, 25 mM).
There are two peaks with minima at 208 and 222 nm, typical of a highly R-helical structure. The 1coi peptide in the headgroup forms a helical structure with 82% helicity. The ratio of the molar ellipticities at 222 and 208 nm is routinely used to identify the presence of coiled-coil helices. For an isolated R-helix, the ratio was estimated to be 0.83, 42 while for interacting R-helices, such as coiled-coils, the ratio was calculated to be ∼1.0. 43 The ratio between the ellipticities at 222 and 208 nm is 1.04, indicating that the tertiary structure of peptides, that is, the coiled-coil helix bundle, is maintained within micelles. The packing parameter that quantifies the shape of amphiphiles was calculated using Israelachvili's surfactant number theory based on the size of the headgroup determined from X-ray and neutron scattering (unpublished results) and the crystal structure of 1coi. The packing parameter of a trimetric subunit, as shown in Scheme 1b, is calculated to be 0.238. For comparison, the packing parameter of individual amphiphiles, as schematically shown in Scheme 1a, is calculated to be 0.332. The formation of 3-helix bundles increased the cross-sectional mismatch between the headgroup and hydrophobic tails. On the basis of Israelachvili's surfactant number theory, the 3-helix bundle peptideÀ PEG conjugate has a strong preference for the formation of spherical micelles. 28 After dissolving the lyophilized amphiphile powder into buffered solution, dynamic light scattering (DLS) (Figure 2b ) reveals a hydrodynamic diameter of 15 nm and a fairly uniform size distribution of micelles. Negatively stained TEM, as shown in Figure 2c , provided further evidence that the amphiphiles form spherical micelles with a diameter of ∼15 nm. Drug Loading. A range of hydrophobic drugs and dye molecules can be readily encapsulated in the micelles including doxorubicin (DOX), dipyrrometheneboron difluoride (BODIPY), and lipophilic carbocyanines for fluorescence imaging. To evaluate the potential of the 3-helix micelles as nanocarriers for therapeutic applications, DOX was used to estimate the drug loading capacity. The encapsulation of DOX in the micelles was performed using a dry-down method. 1coi-dC18-PEG2K and DOX were first solubilized in methanol, dried, and rehydrated. After spin dialysis to remove free drugs, size exclusion chromatography (SEC) and DLS were used to characterize the homogeneity of the DOX-loaded micelles. As shown in Figure 3a , the overlapping elution profiles of the micelles monitored at 220 and 480 nm that monitor the peptide and DOX, respectively, verified the encapsulation of doxorubicin in the micelles and the absence of free drug. DLS experiments (Figure 3b) indicate that the addition of DOX did not disrupt the uniformity of the micelles, showing a single species with a diameter of 15 nm. Quenching of DOX fluorescence in micelles, compared to free DOX in solution, further confirmed the presence ARTICLE of DOX in the micelles (Figure 3c ). The DOX loading was determined by dissolving the lyophilized powder in methanol and monitoring the absorbance of the DOX at 480 nm. For both free DOX solution and DOXencapsulated micelles, DOX concentration was the same based on UV absorbance at 480 nm. Thus, the fluorescence intensity shown in Figure 3c reflects the different local environment of DOX molecules. For DOX, drug loading in the range of 7À8 wt % was obtained reproducibly. This is comparable to the values obtained by covalent conjugation of DOX to dendrimers 44 and polypeptides, 25 where 4À10 wt % has been reported.
In Vitro Stability by FRET. The entrapped drug must be maintained inside the carriers until reaching the target site; however, in vivo cargo leakage remains a longstanding issue for micellar nanocarriers. For dye-loaded block copolymer (BCP) micelles, in vivo FRET studies showed that dye molecules were released 15 min after intravenous injection. 45 The in vitro stability of the 3-helix micelles was evaluated using FRET in the presence of bovine serum albumin (BSA), which is known as an amphiphile trap that disrupts micellar nanocarriers. 31, 46 A lipophilic FRET pair, 3,3 0 -dioctadecyloxacarbocyanine perchlorate (DiO, donor) and 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine perchlorate (DiI, acceptor), Figure 1 . Synthetic scheme and MALDI spectrum of amphiphilic peptideÀpolymer conjugates. The postmodification of peptide 1coi was achieved through selective protectionÀdeprotection strategy employed in Fmoc solid-phase peptide synthesis. Specifically, the alkyl chains were conjugated on solid phase through reaction of stearic acids with deprotected Fmoc-Lys(Fmoc)-OH to generate a branched alkyl tail. The C-terminus was modified through palladium-catalyzed allyl deprotection of FmocLys(Alloc)-OH followed by the conjugation of carboxy-terminated PEG (M w = 750 Da) using HBTU/DIPEA chemistry. After TFA cleavage reaction, maleimide end-functionalized PEG2000 was appended in the middle of the peptide domain through site-specific Michael addition reaction. The conjugate was purified by reverse-phase high-pressure liquid chromatography (RP-HPLC) using a gradient of mixed solvents containing water (0.1% TFA) and isopropyl alcohol (0.1% TFA). The amphiphilic molecules were eluted at ∼85% isopropyl alcohol. The overall purification yield is around 30%. The molecular weight was confirmed by MALDI-TOF spectrometry. The distance between neighboring peaks is 44 Da, corresponding to the mass of a PEG repeat unit.
were coencapsulated in 1coi-dC18-PEG2K micelles. As the control experiment, the same FRET dyes were coencapsulated in conventional micelles based on 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2K). Dye-encapsulated micelles were diluted in a physiological concentration of BSA (50 mg/mL) at 37°C, and fluorescence was monitored in the range of 475À600 nm with λ ex = 450 nm.
After initial equilibration in BSA (∼10 min), a major emission peak is observed at 565 nm, which is accompanied by a minor emission peak at 505 nm. This indicates that both dyes are encapsulated within individual micelles and arranged in close proximity. If the ARTICLE cargo molecules leach out, FRET turns "off" due to the increase in the intermolecular distance between DiO and DiI, resulting in a simultaneous increase of fluorescence intensity at 505 nm and decrease at 565 nm. For 1coi-dC18-PEG2K micelles, over time, the fluorescence intensity remains essentially unchanged at both 505 and 565 nm (Figure 4a ). In contrast, for DSPE-PEG2K micelles, the intensity at 565 nm drops significantly, which is accompanied by an increase in fluorescence intensity at 505 nm (Figure 4b) . The FRET ratio of I 565 /(I 565 þ I 505 ) represents the efficiency of energy transfer and reflects the relative stability of micelles under the experimental conditions (Figure 4c) . 30, 45, 47 A sharp decrease of the normalized FRET ratio is observed for DSPE-PEG2K micelles, indicating rapid cargo release out of micelles in BSA solution, whereas the ratio remains essentially constant for 3-helix micelles under the same conditions ( Figure 4c ). This result is consistent with previously reported results indicating that DSPE-PEG2K micelles have poor stability in BSA with a half-life of 20 min at 37°C.
31
In Vivo Studies of 3-Helix Micelles Using PET Imaging. Pharmacokinetic evaluation and biodistribution of the 3-helix micelles were carried out to validate their potential as nanocarriers. The preparation of 64 Culabeled 3-helix micelles was achieved by co-assembly of metal-chelator-functionalized amphiphilic peptides with the regular amphiphilies followed by high affinity coordination reaction with 64 Cu ions. The detailed synthetic and labeling procedures are presented in the Supporting Information. Micelle solutions were administered through intravenous injection to mice bearing NDL tumors. Using positron emission tomography (PET), the pharmacokinetics of radiolabeled micelles was assessed and compared with longcirculating liposomes 48 and conventional DSPE-PEG2K micelles. All tested micelles have similar degrees of hydrophobicity, as they are composed of double C18 tails and a stealth layer of PEG to prevent nonspecific protein adsorption. PET images were acquired over 48 h after injection and demonstrated that the 3-helix micelles remained highly concentrated in the blood pool, with minimal liver and spleen accumulation (Figure 5a ). Approximately 15 ( 1.5% ID/g remained circulating in the blood pool at 48 h post-injection (Figure 5b ). The activity was confined to plasma rather than the circulating cellular components (Figure 5c ). On the basis of the image data set, the pharmacokinetics of the 3-helix micelle was fitted using a biphase model. The β-phase blood circulation half-life (t 1/2,β ) of the micelles was estimated to be ∼29.5 h (Figure 5b ), which is comparable to that of successful dendrimerÀDOX conjugate showing a circulating half-life of 16 h and antitumor activity in a carcinoma model. 22, 44 The half-life is in a range similar to those of polypeptide-based block copolymer micelles currently in clinical trials.
49 Figure 6 shows the comparison of the biodistribution profile of the 3-helix micelles with long-circulating liposomes and conventional DSPE-PEG2K-OMe micelles in nonperfused mice. The radioactivity resulting from injection of 3-helix micelles is the highest in the blood pool with 15.0 ( 1.5% ID/g. The uptake of the 3-helix micelles in NDL model tumors (5.7 ( 0.9% ID/g) was similar to that achieved with 64 Cu-liposomes (4.3% ID/g) and 64 Cu-albumin in a similar model (MIN-O) and may be attributed to the EPR effect. 50 The radioactivities of different organs are observed as follows: 4.6 ( 0.5% ID/g in the spleen, 4.5 ( 0.2% ID/g in the liver, 2.9 ( 0.3% ID/g in the kidney, 2.1 ( 0.2% ID/g in the heart. The animals were not perfused in our study. Considering that the high activity remained in blood at the point of the biodistribution study, the residual 
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blood in liver and spleen may partially account for the activities observed in these organs. To further clarify the systemic clearance pathway, radioactivities in the duodenum and jejunum were measured, which are ∼2% ID/g (Figure 6a ). The low activity in the digestion system, liver, and spleen indicated that the reticuloendothelial systems (RES) clearance may not be the primary clearance pathway for the 3-helix micelles. The radioactivity detected within the blood, liver, and spleen was also compared among the 3-helix micelles, DSPE-PEG2K-OMe micelles, and long-circulating liposomes (Figure 6b ). Due to the rapid clearance of DSPE-PEG2K-OMe micelles, biodistribution results at 24 h were used for comparison to those obtained at 48 h with long-circulating liposomes and 3-helix micelles. The radioactivity in the liver resulting from DPSE-PEG2K-OMe micelles remained at a similar level to that of long-circulating liposomes. Substantial differences between 3-helix micelles and long-circulating liposomes were apparent: blood circulation was extended, and liver and spleen accumulation was decreased compared with either previous strategy. Cu-1coi-dC18-PEG2K micelles. Statistical analysis between groups was performed with one-way ANOVA followed by Tukey's multiple comparison test (***P < 0.0001, **P < 0.001, *P < 0.05).
In vivo pharmacokinetics and biodistribution studies clearly demonstrated that 3-helix micelles achieved long circulation half-life and efficient clearance. We attribute the long circulation half-life to the micelle size, physical stability, and surface chemistry. Reduced accumulation in the liver, spleen, and intestine, combined with urinary activity, suggests that the 3-helix micelle was not primarily cleared through the RES pathway. One hypothesis for the systemic clearance of 3-helix micelles is first by monomer desorption, where individual or trimeric amphiphiles exit the micelle during blood circulation. If the hydrophobic C18 tails cannot be shielded by the headgroup, the amphiphiles will be captured by serum proteins and subsequently cleared by the RES system, 51 similar to results of other micelles, including DSPE-PEG2K and block-copolymer-based micelles. As the hydrophilic headgroup (i.e., 1coi-PEG2K) is over 5 kDa in molecular weight, it is possible that 1coi-PEG2K may wrap the C18 chains to shield nonfavorable interactions between C18 and water. This is similar to our recent studies in 1coiÀpolystyrene conjugates where the 1coi unfolded and acted as a surfactant for the hydrophobic PS. 52 The molecular weight of the 1coi-dC18-PEG2K amphiphile is only ∼6 kDa, well below the critical molecular weight cutoff to pass through the glomerular membranes. In the sequence of the 1coi peptide, there are a few sites that can be cleaved by proteases. As an alternative to physical desorption of micelles, the 3-helix micelles can be internalized into cells and digested via proteolysis. Once the peptide is enzymatically degraded, the micelle will disassemble and the fragments of the amphiphile will be metabolized.
CONCLUSIONS
In summary, we demonstrated a new design to prepare stable micelles based on amphiphilic 3-helix peptideÀpolymer conjugates. Our design is unique in two ways; that is, the helical peptide self-associates to form a common protein tertiary structure, coiled-coil helix bundle, and the PEG is covalently attached to the middle of the peptide helix and to the exterior of the helix bundle. The quantification of the energetic contributions from each component of the amphiphile is ongoing. However, our initial investigation suggests that it is the combination of these two factors that leads to exceptional stability of 3-helix micelles. Quantitative studies may open up a new avenue to generate organic nanoparticles with tunable stability, ligand clustering, and controlled disassembly and will be the focus of a later contribution. Present studies clearly demonstrate that these newly designed 3-helix micelles have many important attributes required for effective drug formulation that are not commonly seen for nanocarriers in this size range. Since each component of the amphiphile can be readily substituted, they also present numerous opportunities for other applications, such as nanocarriers with active targeting, vaccine formulation, delivery of peptide-based drugs, inhibitors and promoters, and nanoreactors for catalysis.
MATERIALS AND METHODS
The 1coi (EVEALEKKVAALECKVQALEKKVEALEHGW) is a de novo designed 3-helix bundle peptide and was synthesized on a Protein Technologies Prelude solid-phase synthesizer using standard 9-fluorenylmethyl carbamate (Fmoc) protection chemistry on PEG-PAL resin (Applied Biosystems), typically at 0.05 mmol scale. Fmoc-Lys(Fmoc)-OH (EMD Bioscience) was appended to the N-terminus to allow coupling of stearic acid molecules to the N-terminus of the peptide. To modify the C-terminus of the peptide with PEG750, Fmoc-Lys(Alloc)-OH was coupled at the C-terminus. The Alloc group was selectively removed by utilizing Pd(PPh3) 4 catalyst and radical trapping agent PhSiH 3 in DCM. The reaction was repeated five times. The resulting free amino groups of lysine were utilized for conjugating carboxy-terminated PEG750 using HBTU/DIPEA chemistry. The coupling reaction was performed at room temperature for 24 h and repeated twice. Peptides were then cleaved from the resin using standard procedures. Cysteine at position 14 facilitates the site-specific coupling of maleimide-functionalized PEG of molecular weight 2000 g/mol to the middle of the peptide sequence. Cysteine at the C-terminus of 1coi-dC18-PEG2K allows for the conjugation of 6-BAT-maleimide onto the peptides for PET imaging.
Negatively Stained Transmission Electron Microscopy. Lyophilized peptide powder was dissolved at 0.1 mg/mL in 25 mM phosphate buffer at pH 7.4. Five microliters of peptide solution was dropped on a discharged holey carbon coated grid (Ted Pella 01824). After removing excess peptide solution, 5 μL of phosphotungstic acid (2 wt %, pH = 3.3) solution was then applied for 2 min. Samples were dried in air and examined by a FEI Tecnai 12 transmission electron microscope at 120 kV.
Förster Resonance Energy Transfer (FRET). A lipophilic FRET pair, 3,3 0 -dioctadecyloxacarbocyanine perchlorate (DiO, donor) and 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine perchlorate (DiI, acceptor), were used to measure the energy transfer upon mixing. Desired amounts of DiO, DiI, and 1coi-dC18-PEG2K or DSPE-PEG2K were codissolved in a mixture of 1:1 chloroform and methanol. Organic solvents were evaporated under vacuum at 60°C for at least 3 h to form a thin film in a glass vial. Phosphate buffer (pH = 7.4, 25 mM) was added to rehydrate the film at a concentration of 1 mg/mL. In cases where visible aggregates were formed, solution was heated in a water bath at 70°C for at least 30 min to promote the homogeneity of the encapsulation. After 24 h stirring at room temperature, the solutions were then subject to centrifugation and spin dialysis to remove any insoluble aggregates and soluble dyes in the supernatant. To 350 μL of the BSA sample was added 10 μL of the dye-encapsulated micelle solution, and time-dependent fluorescence intensity was recorded in the range of 475 to 650 nm for 12 h with excitation wavelength at 450 nm.
MicroPET Imaging and Biodistribution Analyses. After the injection of 64 Cu-1coi-dC18-PEG2k micelles, female FVB mice (n = 6) bearing NDL tumors bilaterally within the mammary fat pads were imaged with microPET and the biodistribution was assessed. In vivo PET scans were obtained for 30 min immediately after tail vein injection of 64 Cu-1coi-dC18-PEG2k micelles ARTICLE (11.7 ( 3.1 MBq and 86 ( 24 nmol lipid per mouse) in 150 μL of PBS and for 30 min at 3, 6, 24, and 48 h after injection. Animals anesthetized with 2À3% isoflurane were placed in pairs on the scanner bed, and PET acquisitions were obtained using a small animal PET scanner (Focus120, Siemens Medical Solutions, Inc.). After final time point scanning of each set of animals, animals were euthanized by cervical dislocation and blood was withdrawn by cardiac puncture. Briefly, once the animals were euthanized, organs were harvested for biodistribution and the radioactivity was measured in a γ-counter (Perkin-Elmer Life Sciences). For the biodistribution of 64 Cu-labeled conventional micelles, two female Balb/c mice weighing 26À27 g (Charles River, MA) were used. 64 Cu-labeled conventional micelles (7.33 ( 0.07 MBq and 69 ( 1 nmol lipids per mouse) were administered via the tail vein; the animals were sacrificed at 24 h after injection due to the rapid clearance of the radioactivity, and the procedures above were followed for biodistribution.
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